SYRE Crosses Above Average Analyst Target
March 05, 2024 at 07:15 AM EST
In recent trading, shares of Spyre Therapeutics Inc (SYRE) have crossed above the average analyst 12-month target price of $30.42, changing hands for $35.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..